|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Device-associated infection rates, mortality, length of stay and bacterial resistance in intensive care units in Ecuador: International Nosocomial Infection Control Consortium's findings显示文摘AIM To report the results of the International Nosocomial Infection Control Consortium(INICC) study conducted in Quito, Ecuador.METHODS A device-associated healthcare-acquired infection(DAHAI) prospective surveillance study conducted from October 2013 to January 2015 in 2 adult intensive care units(ICUs) from 2 hospitals using the United States Centers for Disease Control/National Healthcare Safety Network(CDC/NHSN) definitions and INICC methods. RESULTS We followed 776 ICU patients for 4818 bed-days. The central line-associated bloodstream infection(CLABSI) rate was 6.5 per 1000 central line(CL)-days, the ventilator-associated pneumonia(VAP) rate was 44.3 per 1000 mechanical ventilator(MV)-days, and the catheterassociated urinary tract infection(CAUTI) rate was 5.7 per 1000 urinary catheter(UC)-days. CLABSI and CAUTI rates in our ICUs were similar to INICC rates [4.9(CLABSI) and 5.3(CAUTI)] and higher than NHSN rates [0.8(CLABSI) and 1.3(CAUTI)]- although device use ratios for CL and UC were higher than INICC and CDC/NSHN's ratios. By contrast, despite the VAP rate was higher than INICC(16.5) and NHSN's rates(1.1), MV DUR was lower in our ICUs. Resistance of A. baumannii to imipenem and meropenem was 75.0%, and of Pseudomonas aeruginosa to ciprofloxacin and piperacillin-tazobactam was higher than 72.7%, all them higher than CDC/NHSN rates. Excess length of stay was 7.4 d for patients with CLABSI, 4.8 for patients with VAP and 9.2 for patients CAUTI. Excess crude mortality in ICUs was 30.9% for CLABSI, 14.5% for VAP and 17.6% for CAUTI. CONCLUSION DA-HAI rates in our ICUs from Ecuador are higher than United States CDC/NSHN rates and similar to INICC international rates. | Estuardo Salgado Yepez Maria M Bovera Victor D Rosenthal Hugo A González Flores Leonardo Pazmino Francisco Valencia Nelly Alquinga Vanessa Ramirez Edgar Jara Miguel Lascano Veronica Delgado Cristian Cevallos Gasdali Santacruz Cristian Pelaéz Celso Zaruma Diego Barahona Pinto | 2017 | World Journal of Biological Chemistry2017，8，1： | 23 |
| 2 | Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: A review of prevalence, diagnosis and clinical significance显示文摘The prevalence of human immunodeficiency virus(HIV) and hepatitis B virus(HBV) co-infection is high as they share similar mechanisms of transmission. The development and widespread use of highly sensitive tests for HBV diagnosis has demonstrated that a significant proportion of apparently healthy individuals with evidence of exposure to HBV continue to carry fully functional HBV DNA in their hepatocytes, a situation that predisposes them to the development of progressive liver disease and hepatocellular carcinoma. The presence of co-infections frequently influences the natural evolution of each of the participating infections present by either facilitating their virulence or competing for resources. Furthermore, the drugs used to treat these infections may also contribute to changes in the natural course of these infections, making the analysis of the impact of co-infection more difficult. The majority of studies has examined the impact of HIV on overt chronic hepatitis B, finding that co-infection carries an increased risk of progressive liver disease and the development of hepatocellular carcinoma. Although the effect of HIV on the natural history of occult hepatitis B infection(OBI) has not been fully assessed, all available data suggest a persisting risk of repeated flares of hepatitis and progressive liver disease. We describe studies regarding the diagnosis, prevalence and clinical significance of OBI in HIVpositive patients in this short review. Discrepancies in worldwide prevalence show the urgent need for the standardization of diagnostic criteria, as established by the Taormina statements. Ideally, standardized protocols for testing should be employed to enable the comparison of data from different groups. Additional studies are needed to define the differences in risk for OBI without HIV and in HIV-HBV co-infected patients with or without overt disease. | Angelica Maldonado-Rodriguez Ana Maria Cevallos Othon Rojas-Montes Karina Enriquez-Navarro Ma Teresa Alvarez-Mu?oz Rosalia Lira | 2015 | World Journal of Hepatology2015，7，2： | 2 |
| 3 | Con- duction and Breakdown Mechanisms in Transformer Oil 显示文摘 | Butcher M Neuber A A Cevallos M D | 2006 | IEEE Transactions on Plasma Science2006，34，2： | 1 |
| 4 | Metabolomic a-nalysis in food science:A review显示文摘 | CEVALLOS J M REYES J I ETXEBERRIA E | 2009 | Trends Food Science and Technology2009，20，1112： | 1 |
| 5 | Molecularcloning and expression of a gene encoding Cryptosporidium parvum glycoproteins Cpgp40/15 显示文摘 | Cevallos A M Zhang X Fayer R | 2000 | Infect Immun2000，68，： | 1 |
| 6 | Minimizing transfer times in public transit network with genetic algorithm 显示文摘 | CEVALLOS F ZHAO F | 2006 | Transportation Research Record: Journal of the Transportation Research Board2006，1971，1： | 1 |
| 7 | Inappropriate treat- ment of catheter - associated asymptomatic bacteriuria in a ter- tiary care hospital 显示文摘 | Trautner BW Cope M Cevallos ME | 2009 | Clinical infectious diseases2009，48，9： | 1 |
| 8 | Cryptosporidium:molecular basis of hostparasite interaction显示文摘 | Ward H Cevallos AM | 1998 | Adv Parasitol1998，40，： | 1 |
| 9 | Cryptosporidium parvum glycoprotein gp40 localizes to the sporozoite surface by association with gp15显示文摘 | O'Connor R M Wanyiri J W Cevallos A M | 2007 | Molecular and biochemical parasitology2007，156，1： | 1 |
| 10 | Twelve cases of pituitary apoplexy显示文摘 | Vidal E Cevallos R Vidal J | 1992 | Arch Intern Med1992，152，9： | 1 |
| 11 | Identification of bacterial pathogens in patients with endophthalmitis by 16S ribosomal DNA typing显示文摘 | KNOX CM CEVALLOS V MARGOLIS TP | | 0，，04： | 1 |
| 12 | Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins Cpgp40/15显示文摘 | Cevallos AM Zhang X Waldor MK | 2000 | Infect Immun2000，68，： | 1 |
| 13 | Clinical and laboratory findings in eighty-five patients显示文摘 | Guillevin L Durand-Gassel B Cevallos R | 1999 | Arthritis Rheum1999，42，： | 1 |
| 14 | Nested case-control study of the emergence of tigecycline resistance in muhidrug-resistant Klebsiella pneumoniae显示文摘 | Nigo M Cevallos CS Woods K | 2013 | Antimicrob Agents Chemother2013，57，11： | 1 |
| 15 | Expresssion of the highly polymorphic Cryptosporidium parvum Cpgp40/15 gene in genotype Ⅰ and Ⅱ isolates显示文摘 | O'Connor RM Thorpe CM Cevallos AM | 2002 | Molecular Biochemical Parasitology2002，119，： | 1 |
| 16 | Stability of anthocyanin- based aqueous extracts of Andean purple corn and red-fleshed sweet potato compared to synthetic and natural colorants显示文摘 | Bolivar A Cevallos C Luis C Z | 2004 | Food Chem2004，6，： | 1 |
| 17 | A site-specific recombinase (RinQ) is required to exert incompatibility towards the symbiotic plasmid of Rhizobium etli显示文摘 | QUINTERO V MIGUEL A CEVALLOS D G | 2002 | Mol Microbiol2002，46，： | 1 |
| 18 | Encapsulation of Cinnamon and Thyme Essential Oils Components (Cinna- maldehyde and Thymol) in β-cyclodextrin: Effect of Interactions with Water on Complex Stability显示文摘 | Ponce Cevallos P A Buera M P Elizalde B E | 2010 | Journal of Food Engineering2010，99，： | 1 |
| 19 | Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins gp40 and gp15显示文摘 | Cevallos A M Zhang X | 2000 | Infection and Immunity2000，68，： | 1 |
| 20 | Assessmento ferythropoietint reat ment i n preter m newbor ns older than 30 week s ofgestation显示文摘 | Fontaine C Cevallos L Leke A | 2009 | Aech Pediatr2009，16，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员